October 12, 2025Transfusion MedicineOpen Access

Tocilizumab provides a potential therapeutic option for the management of hyperhaemolysis syndrome in sickle cell disease: A case series and brief narrative overview of the literature

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Case series reveals rapid resolution of haemolysis with tocilizumab in sickle cell disease patients, suggesting a new treatment avenue.

Tocilizumab led to rapid resolution of haemolysis in all four treated cases of hyperhaemolysis syndrome.
In two cases, patients received transfusions post-treatment with no recurrence of haemolysis, demonstrating efficacy.
Clinical data from specialist haemoglobinopathy centres highlighted the potential of tocilizumab as a cost-effective treatment.
Two patients unfortunately died from unrelated causes, indicating ongoing risks associated with sickle cell disease.

Wolf et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark